The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers,BJU International

当前位置： X-MOL 学术 › BJU Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers
BJU International ( IF 3.7 ) Pub Date : 2024-06-05 , DOI: 10.1111/bju.16432
Elizabeth K Bancroft _{1,

2} , Elizabeth C Page ₂ , Mark N Brook ₂ , Jennifer Pope ₂ , Sarah Thomas ₁ , Kathryn Myhill ₁ , Brian T Helfand ₃ , Pooja Talaty ₃ , Kai-Ren Ong ₄ , Emma Douglas ₄ , Jackie Cook ₅ , Derek J Rosario ₆ , Monica Salinas ₇ , Saundra S Buys ₈ , Jo Anson ₈ , Rosemarie Davidson ₉ , Mark Longmuir ₉ , Lucy Side ₁₀ , Diana M Eccles _{10,

11} , Marc Tischkowitz _{12,

13} , Amy Taylor ₁₂ , Mara Cruellas ₁₄ , Eduard Perez Ballestero ₁₄ , Ruth Cleaver ₁₅ , Mohini Varughese ₁₅ , Julian Barwell _{16,

17} , Mandy LeButt ₁₇ , Lynn Greenhalgh ₁₈ , Rachel Hart ₁₈ , Ashraf Azzabi ₁₉ , Irene Jobson ₁₉ , Lynn Cogley ₂₀ , D Gareth Evans ₂₁ , Jeanette Rothwell ₂₁ , Natalie Taylor ₁ , Matthew Hogben ₁ , Sibel Saya _{2,

22} , , Rosalind A Eeles _{1,

2} , Neil K Aaronson ₂₃

Affiliation

Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.
Oncogenetics Team, Institute of Cancer Research, London, UK.
Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA.
West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, Birmingham, UK.
Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK.
Royal Hallamshire Hospital, Sheffield, UK.
Hereditary Cancer Program, ICO (Catalan Institute of Oncology), Barcelona, Spain.
Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
West of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK.
Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.
The University of Southampton Medical School, Southampton, UK.
East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.
Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK.
Hereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Peninsula Clinical Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK.
University of Leicester, Leicester, UK.
University Hospitals Leicester, Leicester, UK.
Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK.
Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK.
Peninsular Genetics, Derriford Hospital, Plymouth, UK.
Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK.
The University of Melbourne, Melbourne, Australia.
Netherlands Cancer Institute, Amsterdam, Netherlands.

To report the long-term outcomes from a longitudinal psychosocial study that forms part of the ‘Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted Screening in men at higher genetic risk and controls’ (IMPACT) study. The IMPACT study is a multi-national study of targeted prostate cancer (PrCa) screening in individuals with a known germline pathogenic variant (GPV) in either the BReast CAncer gene 1 (BRCA1) or the BReast CAncer gene 2 (BRCA2).

中文翻译：

BRCA1 和 BRCA2 携带者前列腺癌筛查的社会心理影响

报告一项纵向心理社会研究的长期结果，该研究构成“具有前列腺癌遗传倾向的男性的识别：对具有较高遗传风险和控制的男性进行针对性筛查”(IMPACT) 研究的一部分。 IMPACT 研究是一项针对乳腺癌癌症基因 1 ( BRCA1 ) 或乳腺癌癌症基因 2 ( BRCA2 ) 中已知种系致病性变异 (GPV) 个体进行靶向前列腺癌 (PrCa) 筛查的多国研究。

更新日期：2024-06-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南